Agios (AGIO) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$98.3M

Revenue (quarter)

$44.7M

Revenue growth (year over year)

+259.25%

Gross profit (trailing twelve months)

$90.5M

Gross margin

91.99%

Net income (trailing twelve months)

−$411.3M

Net income (quarter)

−$100.7M

Net income growth (year over year)

+10.10%

Net margin

−418.24%

Return on equity

−34.34%

EPS (trailing twelve months)

−$7.01

Book value per share

$17.21

P/E (trailing twelve months)

—

Price to book

1.80

Debt to assets

7.43%

Payout ratio

—

Dividend yield

—

Company profile

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.

• Is Agios (AGIO) profitable?

  No. Agios reported a net loss of $411.3M over the trailing twelve months.

• How much revenue does Agios (AGIO) make?

  Agios generated $98.3M in revenue over the trailing twelve months, up 259.25% year over year.

• How do I buy stock in Agios (AGIO)?

  AGIO trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.